Cat. No.: HY-N0805

Alisol B 23-acetate

(Synonyms: 23-Acetylalismol B; 23-O-Acetylalisol B; Alisol B monoacetate)

3 Cited Publications

Customer Review

Based on 3 publication(s) in Google Scholar

Alisol B 23-acetate is an orally active prototerpane-type triterpenoid. Alisol B 23-acetate can be isolated from Alisma orientalis. Alisol B 23-acetate induces Apoptosis, promotes ROS generation, downregulates CDK4/6, MMP-2/9, upregulates cleaved PARP, activates FXR and inhibits Syk. Alisol B 23-acetate has anti-inflammatory and hepatoprotective activities. Alisol B 23-acetate protects the kidney from ischemia-reperfusion injury. Alisol B 23-acetate has anticancer activity against ovarian cancer, colon cancer, lung cancer, and gastric cancer. Alisol B 23-acetate can be used in the study of atherosclerosis and allergic asthma.

For research use only. We do not sell to patients.

Purity: 99.65%
CAS No.: 26575-95-1
Formula: C₃₂H₅₀O₅
Molecular Weight:514.74

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Alisol B 23-acetate Chemical Structure

CAS No.: 26575-95-1

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (3)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]^[21]^[3]^[4]^[5]^[6]^[7]^[8]^[9]^[10]^[11]^[12]^[13]^[14]

CDK4

CDK6

MMP-2

MMP-9

All CDK Isoforms :

All MMP Isoforms :

All PARP Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
Erythrocyte	IC₅₀	12.8 μM Compound: 57b	Antiplasmodial activity against Plasmodium falciparum K1 infected in human erythrocyte assessed as inhibition of parasite growth incubated for 72 hrs by [3H]-hypoxanthine incorporation based liquid scintillation counting method Antiplasmodial activity against Plasmodium falciparum K1 infected in human erythrocyte assessed as inhibition of parasite growth incubated for 72 hrs by [3H]-hypoxanthine incorporation based liquid scintillation counting method	[PMID: 35985254]
HepG2	EC₅₀	3.57 μM Compound: 26	Transactivation of FXR (unknown origin) transfected in HepG2 cells co-expressing pBSEP/pGL4.74 incubated for 24 hrs by luciferase reporter gene assay Transactivation of FXR (unknown origin) transfected in HepG2 cells co-expressing pBSEP/pGL4.74 incubated for 24 hrs by luciferase reporter gene assay	[PMID: 31494470]

In Vitro

Alisol B 23-acetate (2.5-20 µM; 24-48 h) significantly inhibits cell viability, induces G₁ phase cell cycle arrest and apoptosis, suppresses migration and invasion in ovarian cancer cell lines A2780, A2780/Taxol, and HEY^[1].
Alisol B 23-acetate (1-100 µM) reverses P-glycoprotein (P-gp)-mediated multidrug resistance in HepG2-DR and K562-DR cells^[2].
Alisol B 23-acetate (5-20 µM; 6-24 h) induces autophagic-dependent apoptosis in human colon cancer cells (HCT116 and SW620) via ROS generation and JNK activation^[3].
Alisol B 23-acetate (20-80 µM; 24 h) improves free fatty acid (FFA)-induced lipid metabolism disorders in L02 hepatocytes^[5].
Alisol B 23-acetate (5-20 μM; 30 min before antigen challenge) inhibits IgE/antigen-mediated β-hexosaminidase release in RBL-2H3 mast cells in a concentration-dependent manner^[14].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

A2780, A2780/Taxol, HEY
Concentration:

5, 6, 9, 10, 12, 15 µM
Incubation Time:

24 h
Result:

Downregulated protein levels of CDK4, CDK6, cyclin D1, MMP-2, MMP-9.
Upregulated Bax/Bcl-2 ratio and cleaved PARP expression.

In Vivo

Alisol B 23-acetate (2.56 mg/kg; p.o.; once daily; 90 days) activates hepatic FXR-BSEP signaling in ovariectomized LDLR^-/- mice, increases fecal cholesterol and bile acid excretion, reduces liver lipid deposition, and ameliorates atherosclerotic lesions^[5].
Alisol B 23-acetate (50-100 mg/kg; p.o.) inhibits IgE-mediated vascular permeability and ear swelling in ICR mouse passive cutaneous anaphylaxis (PCA) model^[7].
Alisol B 23-acetate (15-30 mg/kg; p.o.; daily; 9 weeks) reduces serum TG, IL-12, IFN-γ, increases HDL-C, and promotes aortic cholesterol efflux gene expression in ApoE^-/- atherosclerotic mice^[8].
Alisol B 23-acetate (10-40 mg/kg; p.o.; 30 days) suppresses TLR4/NOX2 pathway, reducing myocardial inflammation and ROS production in LPS-induced cardiac dysfunction mice^[9].
Alisol B 23-acetate (15-60 mg/kg; p.o.; daily; 4 weeks) ameliorates hepatic steatosis, inflammation, and fibrosis, and activates FXR target genes in MCD-induced NASH mice^[10].
Alisol B 23-acetate (12.5-50 mg/kg; p.o.; once daily; 7 days) promotes liver regeneration in mice after partial hepatectomy via activating farnesoid X receptor^[11].
Alisol B 23-acetate (10-40 mg/kg; p.o.; once daily; 7 days) alleviates hepatotoxicity in a dose-dependent manner in CCl₄ (HY-Y0298)-induced liver injury mice^[12].
Alisol B 23-acetate (60 mg/kg; i.p.; 30 min before sensitization/challenge) reduces airway hyperresponsiveness and decreases IL-13 and eosinophils in BALF in OVA-induced allergic asthma BALB/c mice^[14].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Adult male C57BL/6 mice (6-8 weeks old), LPS-induced sepsis model^[9].
Dosage:

10 mg/kg, 20 mg/kg, 40 mg/kg
Administration:

Gavage (p.o.), 30 days
Result:

Significantly improved the 48-hour survival rate of LPS-induced septic mice (80% in the 40 mg/kg group vs. 40% in the LPS group).
Restored left ventricular ejection fraction (LVEF), left ventricular fraction shortening (LVFS), and reduced left ventricular end-systolic diameter (LVESD) in LPS-treated mice.
Reduced inflammatory cell infiltration in myocardial tissue.
Decreased serum levels of TNF-α, IL-6, and IL-1β.
Downregulated TLR4, NOX2, p-P38, and p-ERK protein expression in myocardial tissue.

Animal Model:

Male C57BL/6 mice (8-9 weeks old) with CCl₄-induced acute hepatotoxicity^[12]
Dosage:

10 mg/kg, 20 mg/kg, 40 mg/kg
Administration:

Oral gavage; once daily; for 7 days
Result:

Significantly reduced serum ALT and AST activities, decreased hepatic and serum total bile acid levels, ameliorated liver histopathological changes (e.g., congestion, vacuolization, necrosis), reduced TUNEL-positive apoptotic hepatocytes.
Increased BrdU-positive proliferating hepatocytes and mitotic index, upregulated FXR target genes (FoxM1b, Cyclin D1, Cyclin B1, Bsep, Mrp2, Shp), and downregulated Ntcp, Cyp7a1, and Cyp8b1 expression.
Enhanced STAT3 phosphorylation and upregulated anti-apoptotic genes (Bcl-xl, SOCS3).

Chemical Information

CAS No. 26575-95-1
Appearance Solid
Molecular Weight 514.74
Formula C₃₂H₅₀O₅
Color White to off-white
SMILES

C[C@]([C@@]1(C2=C([C@H](C)C[C@@H]([C@]3([H])C(C)(C)O3)OC(C)=O)CC1)C)(CC[C@@]4([H])C5(C)C)[C@]([C@H](C2)O)([H])[C@]4(CCC5=O)C
Synonyms

23-Acetylalismol B; 23-O-Acetylalisol B; Alisol B monoacetate
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (3)

All

Sort by:

Journal Impact Factor

CNS Neurosci Ther

ShenQi DiHuang Decoction (SQDHD) Ameliorates Neuroinflammation and Neuropsychiatric Manifestations in Pristane Induced Lupus Mice via Blocking JAK1-STAT3 Pathway. [Abstract]

2026 Mar;32(3):e70814. PMID: 41795136
J Integr Med

Alisol B 23-acetate promotes white adipose tissue browning to mitigate high-fat diet-induced obesity by regulating mTOR-SREBP1 signaling. [Abstract]

2024 Jan;22(1):83-92. PMID: 38311542
Res Sq

2025 Jul 24.

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (97.14 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9427 mL

9.7136 mL

19.4273 mL

5 mM

0.3885 mL

1.9427 mL

3.8855 mL

10 mM

0.1943 mL

0.9714 mL

1.9427 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.86 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.86 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.86 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (289 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Zhang LL, et al. Effects of alisol B 23-acetate on ovarian cancer cells: G1 phase cell cycle arrest, apoptosis, migration and invasion inhibition. Phytomedicine. 2016 Jul 15;23(8):800-9. [Content Brief]

[2]. Wang C, et al. Reversal of P-glycoprotein-mediated multidrug resistance by Alisol B 23-acetate. Biochem Pharmacol. 2004 Sep 1;68(5):843-55. [Content Brief]

[3]. Zhao Y, et al.Alisol B 23-acetate induces autophagic-dependent apoptosis in human colon cancer cells via ROS generation and JNK activation. Oncotarget. 2017 Jul 26;8(41):70239-70249. [Content Brief]

[4]. Wang J, et al. Alisol B-23-acetate, a tetracyclic triterpenoid isolated from Alisma orientale, induces apoptosis in human lung cancer cells via the mitochondrial pathway. Biochem Biophys Res Commun. 2018 Nov 10;505(4):1015-1021. [Content Brief]

[5]. Fu Y, et al. Alisol B 23-acetate adjusts bile acid metabolisim via hepatic FXR-BSEP signaling activation to alleviate atherosclerosis. Phytomedicine. 2022 Jul;101:154120. [Content Brief]

[6]. Kwon MJ, et al. Apoptotic effects of alisol B 23‑acetate on gastric cancer cells. Mol Med Rep. 2021 Apr;23(4):248. [Content Brief]

[7]. Shao C, et al. Alisol B 23-Acetate Inhibits IgE/Ag-Mediated Mast Cell Activation and Allergic Reaction. Int J Mol Sci. 2018 Dec 18;19(12):4092. [Content Brief]

[8]. Sun Y, et al. Alisol B 23-acetate, a new promoter for cholesterol efflux from dendritic cells, alleviates dyslipidemia and inflammation in advanced atherosclerotic mice. Int Immunopharmacol. 2021 Oct;99:107956. [Content Brief]

[9]. Wang B, et al. Alisol B 23-Acetate Ameliorates Lipopolysaccharide-Induced Cardiac Dysfunction by Suppressing Toll-Like Receptor 4 (TLR4)/NADPH Oxidase 2 (NOX2) Signaling Pathway. Med Sci Monit. 2019 Nov 10;25:8472-8481. [Content Brief]

[10]. Meng Q, et al. Alisol B 23-acetate protects against non-alcoholic steatohepatitis in mice via farnesoid X receptor activation. Acta Pharmacol Sin. 2017 Jan;38(1):69-79. [Content Brief]

[11]. Meng Q, et al. Alisol B 23-acetate promotes liver regeneration in mice after partial hepatectomy via activating farnesoid X receptor. Biochem Pharmacol. 2014 Nov 15;92(2):289-98. [Content Brief]

[12]. Meng Q, et al. Protective effects of alisol B 23-acetate from edible botanical Rhizoma alismatis against carbon tetrachloride-induced hepatotoxicity in mice. Food Funct. 2015 Apr;6(4):1241-50. [Content Brief]

[13]. Luan ZL, et al. A naturally occurring FXR agonist, alisol B 23-acetate, protects against renal ischemia-reperfusion injury. Am J Physiol Renal Physiol. 2021 Nov 1;321(5):F617-F628. [Content Brief]

[14]. Nam KH, et al. Alisol B 23-Acetate Ameliorates Ovalbumin-Induced Allergic Asthma during Sensitization and Challenge Periods. Biomol Ther (Seoul). 2023 Nov 1;31(6):611-618. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9427 mL	9.7136 mL	19.4273 mL	48.5682 mL
	5 mM	0.3885 mL	1.9427 mL	3.8855 mL	9.7136 mL
	10 mM	0.1943 mL	0.9714 mL	1.9427 mL	4.8568 mL
	15 mM	0.1295 mL	0.6476 mL	1.2952 mL	3.2379 mL
	20 mM	0.0971 mL	0.4857 mL	0.9714 mL	2.4284 mL
	25 mM	0.0777 mL	0.3885 mL	0.7771 mL	1.9427 mL
	30 mM	0.0648 mL	0.3238 mL	0.6476 mL	1.6189 mL
	40 mM	0.0486 mL	0.2428 mL	0.4857 mL	1.2142 mL
	50 mM	0.0389 mL	0.1943 mL	0.3885 mL	0.9714 mL
	60 mM	0.0324 mL	0.1619 mL	0.3238 mL	0.8095 mL
	80 mM	0.0243 mL	0.1214 mL	0.2428 mL	0.6071 mL

Alisol B 23-acetate

3 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Alisol B 23-acetate

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Protein Tyrosine Kinase Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Covalent Screening Library

Differentiation Inducing Compound Library

Anti-Cardiovascular Disease Compound Library

Terpenoids Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Angiogenesis-Related Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Pulmonary Fibrosis Compound Library

Nuclear Receptor Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Metabolic Enzyme Compound Library

Protease Inhibitor Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

High-Efficiency Gene Editing Compound Library

Natural Product Diversity Scaffold Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Alisol B 23-acetate

All CDK Isoforms

All MMP Isoforms

All PARP Isoforms

Biological Activity

Chemical Information

Publications (3)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Alisol B 23-acetate Related Classifications

HY-N0805 Related Classifications